Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO ODT versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO ODT versus MYDAYIS.
EVEKEO ODT vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant